Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir

Hepatology Research

Volumn 45, Issue 10, 2015, Pages E156-E160

  Okajima, Akira ^a   Yamaguchi, Kanji ^a   Taketani, Hiroyoshi ^a   Hara, Tasuku ^a   Ishiba, Hiroshi ^a   Seko, Yuya ^a   Nishimura, Takeshi ^a   Nishikawa, Taichiroh ^a   Fujii, Hideki ^a   Moriguchi, Michihisa ^a   Mitsuyoshi, Hironori ^a   Sumida, Yoshio ^a   Yasui, Kohichiroh ^a   Minami, Masahito ^a   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Drug induced liver injury; Hepatitis C; Simeprevir

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INTERLEUKIN 28B; MITOCHONDRION ANTIBODY; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; URSODEOXYCHOLIC ACID; VALPROIC ACID;

ABDOMINAL RADIOGRAPHY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHRONIC HEPATITIS C; DISEASE SEVERITY; DRUG WITHDRAWAL; EPILEPSY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER DYSFUNCTION; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; RELAPSE; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 84945471499     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12477     Document Type: Article

References (16)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
2. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Supp1): 88-102.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Disease. Hepatology 2011; 54: 1433-44.
4. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
5. Kikuchi H, Numao H. Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2014; 26: 244-5.
6. Hayashi N, Izumi N, Kumada H et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a Phase III trial. J Hepatol 2014; 61: 219-27.
7. Izumi N, Hayashi N, Kumada H et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-53.
8. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010; 52: 461A [Abstract].
9. Takigawa H, Onji N, Takamori Y et al. Proposal of diagnostic criteria of drug induced hepatic injury in DDW-J2004 workshop. Kanzo 2005; 46: 85-90.
10. FDA Antiviral Drugs Advisory Committee Meeting. Background Package for NDA 205123 Simeprevir (TMC435). October 24, 2013. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371623.pdf. Accessed June 6, 2014.
11. Lee SJ, Lee SS, Jeong HE et al. The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos 2007; 11: 2095-101.
12. Yamamoto T, Nagafuchi N, Ozeki T et al. SNP communication CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 2003; 18: 267-8.
13. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
14. Abdel-Dayem MA, Elmarakby AA, Abdel-Aziz AA, Pye C, Said SA, El-Mowafy AM. Valproate-Induced liver injury: modulation by the omega-3 fatty Acid DHA proposes a novel anticonvulsant regimen. Drugs R&D 2014; 14: 85-94.
15. Silva MF, Aires CC, Luis PB et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008; 31: 205-16.
16. Chadwick B, Waller DG, Edwards JG. Potentially hazardous drug interactions with psychotropics. Adv Psychiatr Treat 2005; 11: 440-9.